

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/041,633	01/10/2002	Akio Kobayashi	111632	6574	
25944 OLIFF & BER	7590 08/27/2007 RIDGE, PLC		EXAMINER		
P.O. BOX 19928			SHAY, DAVID M		
ALEXANDRIA, VA 22320			ART UNIT	PAPER NUMBER	
			3735		
			MAIL DATE	DELIVERY MODE	
			08/27/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.



	Application No.	Applicant(s)				
Office Action Commence	10/041,633	KOBAYASHI ET AL.				
Office Action Summary	Examiner	Art Unit				
	david shay	3735				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status	•					
1) Responsive to communication(s) filed on June	<u>22, 2007</u> .					
•	action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1,2,5-10,13 and 14</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) <u>1, 2, 5-10, 13, and 14</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers		• .				
9) The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
· .	,					
Attachment(s)	• - <u></u>					
1) Notice of References Cited (PTO-892)	4) Interview Summary Paper No(s)/Mail Da					
3) Information Disclosure Statement(s) (PTO/SB/08) 5) Notice of Informal Patent Application						
Paper No(s)/Mail Date 6)						

Applicant has submitted new drawings. These drawings are not acceptd, as they contain new matter, e.g. the taper of the glass chip. The examiner has thoroughly reviewed the specification in view of the drawings, and the discussion during the interview of June 15, 2007. After this review, it appears that the examiner's determination of the need for additional drawings was erroneous. It appears, from the disclosure, that the "quartz glass chip" and the "quartz capillary" can be one and the same structure (however, it appears that the term "quartz capillary" in the context of the instant disclosure, can also indicate a simple capillary tube that has not been processed, i.e. tapered and coated with metal, to be a "quartz glass chip"). As such, Figure 1 is a sufficient illustration of this structure for the purposes of enablement, and a modification of this Figure with an arrow indicating the laser light energy and a legend indicating the quartz glass chip would satisfy the examiner's drawing objections.

The drawings are objected to under 37 CFR 1.83(a). The drawings must show every feature of the invention specified in the claims. Therefore, the "laser beam with 1-100 mJ/cm² of energy density energy output"; and "introducing foreign matter" must be shown or the feature(s) canceled from the claim(s). No new matter should be entered.

Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as "amended." If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the

drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either "Replacement Sheet" or "New Sheet" pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.

With regard to the art rejection, applicant acknowledges that Abela et al ('982) teaches the use of a hollow optical fiber to deliver genetic material to cells. This is done by porating the cell: incising the cell membrane to allow the passage of the genes into the interior portion thereof. Applicant argues that Matsuura et al (1998) do not teach irradiating a living cell. However, since Abela et al ('982) already teaches this, it is not necessary for Matsuura et al (1998), which teaches medical applications, generally, to do so as well. With regard to the Lewis et al reference, applicant argues that Lewis et al is directed to providing precise cuts in tissue, for reasons that are unclear to the examiner, applicant appears to conclude the since the tapered tip of Lewis et al is used for providing precise cuts to tissue, that there is no motivation to combine the teaching with that of Abela et al ('982), which requires precise cuts in the tissue of the cell walls. However, since the precise portions of the cell walls which are ablated in Abela et al ('982) would be more precisely ablated by using the tapered tips of Lewis et al, thereby allowing more cells to remain viable and express the genotypes intended to be transferred to the cells in Abela et al ('982), this appears to the examiner to be a motivation to person having ordinary skill in the art to make the combination, rather than a deterrent.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claims 1, 2, 5-10, 13 and 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Abela et al ('982) in combination with Matsuura et al (1998), Kubota et al, and Lewis et al. Abela et al ('982) teach the method as claimed except for the specific recitation of the use of a hollow fiber, the specific laser energies, or the quartz chip (please note that the absence of the quartz chip implies the absence of other structures predicated thereon, such as the hydroxide groups). Matsuura et al (1998) teaches forming hollow waveguides for the delivery of excimer laser light from hollow fibers that are coated with aluminum and are filled with an inert gas. Lewis et al teaches the desirability of using a wave guiding device with a tapered tip in a medical system and method for applying high energy radiation. Kubota et al teach that producing holes in cell walls can be done using energy densities between 50 and 250 mJ/cm² with 193 nm light (see column 5, line 17-23). Lewis et al teach the desirability of providing a tapered structure on the distal end of a hollow optical fiber delivering 193 nm radiation. It would have been obvious to the artisan of ordinary skill to employ a device and method as taught by Abela et al ('982) in the device and method of Matsuura et al (1998) since Matsuura et al (1998) specifically discloses the desirability of using hollow waveguides in medical applications; or to use the device and method of Matsuura et al (1998) in the device and method of Abela et al ('982), since Abela et al ('982) disclose no particular fibers and since these fibers efficiently transmit high energy radiation while exhibiting favorable bending radii; and in either case to employ the tapered tip of Lewis et al, since this provides beam sizes in the range required by Abela et al ('982); or to employ the tapered tip of Lewis et al on the waveguide of Abela et al ('982), since this provides

Page 5

Art Unit: 3735

beam sizes in the range required by Abela et al ('982), or to employ the device and method of Abela et al ('982) in the device and method of Lewis et al, since Lewis et al disclose drilling through cell walls as a preferred use of the device, and in either case to employ the hollow waveguide of Matsuura et al (1998), since this allows for the transmission of greater energies and avoids the formation of color centers, which is a problem, as taught by Lewis et al; or to provide the method and device of Lewis et al in the method and device of Matsuura et al (1998), since the tapered tip of Lewis et al provides greater energies and or to provide the method and hollow waveguide device of Matsuura et al (1998) in the device and method of Lewis et al, since this would avoid the production of color centers and enable larger energies to be delivered, and in either case to employ the method and device of Abela et al since this is a medical method as suggested by Matsuura et al (1998), which would benefit from the delivery of high energy radiation and since this device and method is useful for drilling into cell walls, as taught by Lewis et al; and in any case, to apply laser energy density in the range claimed, since can be used to produce holes in cell walls, as taught by Kubota et al; to employ a chip as claimed, since this condenses the light and is commercially available, as taught at paragraph [0051] of the instant disclosure; to use any of the claimed inert gasses, since these are all well known inert gasses in the art, are not critical and provide no unexpected result, thus producing a method such as claimed.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1, 2, 5-10, 13 and 14 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-12 of U.S. Patent No. 7,132,289. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of the patent anticipate the claims of the application. Accordingly, instant application claims are not patentably distinct from the patent claims. Here, the patent claims require elements A, B, C, and D while instant application claim 1 only requires elements A, B, and C. Thus it is apparent that the more specific patent claims encompass the instant application claims. Following the rationale in In re Goodman cited in the preceding paragraph, where applicant has once been granted a patent containing a claim for the specific or narrower invention, applicant may not then obtain a second patent with a claim for the generic or broader invention without first submitting an appropriate terminal disclaimer.

Applicant's arguments filed February 7, 2007 have been fully considered but they are not persuasive. The arguments are not persuasive for the reasons set forth above.

Applicant's arguments with respect to claims 1, 2, 5-10, 13, and 14 have been considered but are moot in view of the new ground(s) of rejection.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to david shay whose telephone number is (571) 272-4773. The examiner can normally be reached on Tuesday through Friday from 6:30 a.m. to 5:00 p.m.

Application/Control Number: 10/041,633 Page 7

Art Unit: 3735

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Charles Marmor, II, can be reached on Monday, Tuesday, Wednesday, Thursday, and Friday. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

DAVID M. SHAY PRIMARY EXAMINER GROUP 330